Company Analysis

Aurinia Pharmaceuticals Inc (AUPH)

Nasdaq: AUPH · Pharmaceutical Preparations · Edmonton, AB · filing with the SEC since 2014
Grade6.8
◀ Past 8.2● Present 6.8▶ Future 5.5

The company now

Aurinia Pharmaceuticals Inc is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Edmonton, AB. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $283 million and a profit of $287 million (its filed statements).

From its filings and filed figures; the desk's account of it is not written yet.

Where the revenue comes from

fiscal 2025, as filed

Revenue by product, fiscal 2025

ProductFiscal 2025Fiscal 2024Share of revenue
Product$271M$216M95.9%
License Collaboration and Royalty Revenue$11.7M$18.9M4.1%

Revenue by region, fiscal 2025

RegionFiscal 2025Fiscal 2024Share of revenue
United States$264M$210M93.2%
Japan$19.2M$25.0M6.8%

As tagged in its annual report (Form 10-K, filed Feb 26, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.

The desk's written account of this company, its Past, Present and Future, is not on file yet.

How the company works

The desk has not read this company's annual report yet.

The record in brief

The desk has not written this company's report yet.

SI Assistanton AUPH · research, not advice